中国基金报·2025-11-06 13:01Core Viewpoint - The China Securities Index Co., Ltd. will officially launch the China Securities Innovation Drug Index and the China Securities Innovation Medical Device Index on November 7, providing a broader range of investment targets for the market [2]. Group 1: Innovation Drug Index - The China Securities Innovation Drug Index selects listed companies involved in innovative drug research and development from the Sci-Tech Innovation Board and the Growth Enterprise Market, reflecting the overall performance of these companies [2]. - A total of 50 constituent stocks have been included in the index, such as BeiGene-U, Zai Lab, and Kanglong Chemical [2]. - Notable performance includes BeiGene-U with a latest closing price of 277.50 yuan per share and a year-to-date increase of 72.34% [4]. Group 2: Medical Device Index - The China Securities Innovation Medical Device Index selects listed companies providing medical devices, consumables, and in vitro diagnostics from the Sci-Tech Innovation Board and the Growth Enterprise Market, reflecting the overall performance of the medical device sector [5]. - The index also includes 50 constituent stocks, including Mindray Medical, United Imaging, and New Industries [5]. - Mindray Medical has a latest closing price of 206.35 yuan per share, with a year-to-date decline of 17.92% [6]. Group 3: Market Trends - The pharmaceutical sector has attracted significant investor attention this year, particularly in the innovative drug space, which has shown remarkable performance [7]. - China's innovative drug pipeline and clinical trial projects rank among the top globally, with ongoing policy support aimed at promoting high-quality industry development [7]. - The medical device industry is also experiencing rapid growth, driven by innovation and the trend of import substitution, as well as global expansion opportunities [8].